정위 체부 방사선 요법으로 치료 중인 전립선암 피험자에 대한 SpaceOAR Vue 시스템의 효과 (SABRE)
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This study is designed to evaluate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in participants undergoing Stereotactic Body Radiotherapy (SBRT) for the treatment of prostate cancer.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Bonn, 독일, D-53129
- MEDICLIN Robert Janker Klinik
-
Nuremberg, 독일, 90419
- Klinikum Nurnberg Nord
-
-
-
-
Florida
-
Fort Myers, Florida, 미국, 33908
- GenesisCare USA
-
Tampa, Florida, 미국, 33609
- Florida Urology Partners, LLC
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- Kansas University Medical Center
-
-
Michigan
-
Troy, Michigan, 미국, 48098
- GenesisCare USA
-
-
New Jersey
-
Bloomfield, New Jersey, 미국, 07003
- New Jersey Urology, a Summit Health Company
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, 미국, 29572
- Dr. John Sylvester
-
-
-
-
-
Basel, 스위스, CH-4031
- University Hospital Basel
-
Bern, 스위스, 3010
- Inselspital - University Hospital Bern
-
-
-
-
-
Barakaldo, 스페인, 48903
- Hospital Universitario Cruces
-
Madrid, 스페인, 28002
- GenesisCare, Hospital San Francisco de Asis
-
Madrid, 스페인
- Hospital Universitario Ramón y Cajal
-
-
-
-
-
Cork, 아일랜드, T12 DV56
- Bon Secours Radiotherapy Cork
-
-
-
-
-
Belfast, 영국, BT9 7AB
- Belfast City Hospital
-
Bristol, 영국, BS2 8ED
- Bristol Haematology and Oncology Centre
-
London, 영국, SW3 6JJ
- Royal Marsden Hospital
-
Norwich, 영국, NR4 7UY
- Norfolk and Norwich University Hospital NHS Trust
-
Plymouth, 영국, PL6 8DH
- Derriford General Hospital
-
-
Surrey
-
Guildford, Surrey, 영국, GU27XX
- Royal Surrey County Hospital NHS Foundation Trust
-
-
Wales
-
Cardiff, Wales, 영국, CF14 2TL
- Velindre Cancer Centre
-
-
-
-
-
Parma, 이탈리아, 43126
- Azienda Ospedaliero Universitaria di Parma
-
Rome, 이탈리아
- Policlinico Universitario Agostino Gemelli
-
Verona, 이탈리아, 37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Levallois-Perret, 프랑스, 92300
- Institut de Radiothérapie & Radiochirurgie HARTMANN
-
-
Cedex
-
Villejuif, Cedex, 프랑스, 94805
- Institut Gustave Roussy
-
-
-
-
New South Wales
-
Waratah, New South Wales, 호주, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Woolloongabba, Queensland, 호주, 4102
- Princess Alexandra Hospital - ROPAIR
-
-
Western Australia
-
Nedlands, Western Australia, 호주, 6009
- Sir Charles Gairdner Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥ 18 years old.
- Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
- Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
- Clinical Stage T2b - T2c (AJCC 6th edition) tumor
- Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.
Exclusion Criteria:
- Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
- Clinical stage T3 or T4 (AJCC 6th edition) tumor
- Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
- Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
- Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
- History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
- History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
- History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
- History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
- Bleeding hemorrhoids requiring medical intervention within the prior three months.
- Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
- Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
- Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
- If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
- Unable to comply with the study requirements or follow-up schedule.
- Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
- Known iodine sensitivity or allergy
- Known polyethylene glycol (PEG) sensitivity or allergy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
간섭 없음: No-Spacer Control
Subjects will receive radiotherapy without the use of the SpaceOAR Vue. |
|
|
실험적: SpaceOAR Vue
Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel. |
The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Late Gastrointestinal (GI) Toxicity
기간: 3 to 24 months post-SBRT initiation
|
Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation |
3 to 24 months post-SBRT initiation
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EPIC-26 bowel score
기간: 24 months post-SBRT initiation
|
Proportion of subjects experiencing a decrease in EPIC-26 bowel score greater than or equal to the minimal important difference (MID) in EPIC-26 bowel score from baseline to 24 months post-SBRT initiation. |
24 months post-SBRT initiation
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Suneil Jain, MB, BCh, PhD, Queen's University, Belfast
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- U0702
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .